You are here:

pregabalin, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg capsules (Lyrica)

Advice

Following a full submission

pregabalin (Lyrica ®) is not recommended for use within NHS Scotland for the treatment of central neuropathic pain in adults.

In a randomised controlled trial pregabalin was superior to placebo in terms of the primary efficacy variable, the weekly mean pain score.

The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by the SMC.

The licence holder has indicated their decision to resubmit.

Drug Details

Drug Name: pregabalin, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg capsules (Lyrica)
SMC Drug ID: 389/07
Manufacturer: Pfizer Ltd
Indication: Central neuropathic pain in adults
BNF Category:
Sub Category: 4.8 Antiepileptic drugs
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 13 August 2007

Back